Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Ephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.71 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.71 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | RGS12 | O14924 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudoephedrine SCHEMBL16601218 | 1.00 | ADRA1A (0.71) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Ephedrine SCHEMBL2501430 | 0.86 | ADRA2C (0.69) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Ephedrine SCHEMBL4785 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Racephedrine SCHEMBL11906521 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Racephedrine SCHEMBL4369 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Ephedrine SCHEMBL4731265 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Racephedrine SCHEMBL12573578 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Pseudoephedrine SCHEMBL4368 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Racephedrine SCHEMBL4786 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR | |
| Racephedrine SCHEMBL8098202 | 0.84 | CYP2D6 (1.00) | ADRA1AADRA2CHTR2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258778-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258738-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170224911-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLU AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-08-10 | — | — | US | disclosed |
| US-20170182299-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE, AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLUE AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-06-29 | — | — | US | disclosed |
| US-20140323423-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS... | CHRONO THERAPEUTICS, INC. (US) | 2014-10-30 | — | — | US | disclosed |